Developing new oral antibiotics to treat resistant bacterial infections
New oral antibiotics focused on treating MDR Gram-negative infections
This study is working on a new type of antibiotic that can help treat tough infections caused by bacteria that don't respond to many current medicines, aiming to create a safe and effective pill for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Curza INC NIH-funded |
| Lab location | 1 site (Salt Lake City, UNITED STATES) |
| Project ID | NIH-11007661 on NIH RePORTER |
What this research studies
This research focuses on creating a new class of antibiotics specifically designed to combat multidrug-resistant (MDR) Gram-negative bacteria. The approach involves developing inhibitors that target a unique site on the bacterial ribosome, which is not affected by existing antibiotics, thereby reducing the risk of cross-resistance. The antibiotics are inspired by natural products but have been engineered to enhance their effectiveness and safety for patients. The goal is to produce a potent, orally administered antibiotic that can effectively treat serious infections caused by resistant bacteria.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients suffering from infections caused by multidrug-resistant Gram-negative bacteria.
Not a fit: Patients with infections caused by non-Gram-negative bacteria or those who do not have antibiotic-resistant infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide patients with new treatment options for infections that are currently difficult to manage due to antibiotic resistance.
How similar studies have performed: Other research has shown promise in developing antibiotics targeting unique bacterial ribosome sites, indicating potential for success in this novel approach.
Where this research is happening
Salt Lake City, UNITED STATES
- Curza INC — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Testa, Charles — Curza INC
- Study coordinator: Testa, Charles
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.